Bayer Ag · XETR:BAYN
Bayer — Technical Presentation (August 2026)
8 slides from Bayer's technical presentation, Aug 30, 2026
Slide 1: Finerenone with Empagliflozin According to Body Mass Index in CKD and Type 2 Diabetes
Finerenone with Empagliflozin According to Body Mass Index in Chronic Kidney Disease and Type 2 Diabetes John W. Ostrominski; Muthiah Vaduganathan; Brian L. Claggett; Janet B. McGill; Jennifer B. Green; Julio Rosenstock; Peter Rossing; Masaomi Nangaku; Meike Brinker; Li Li; Na Li; Charlie Scott; Raj
Slide 2: Background
Background • Obesity is an important driver of CKD Temporal Change in UACR, by Assigned Treatment in the CONFIDENCE Trial and type 2 diabetes (T2D) • Obesity and body weight change can influence the effects of CKD therapies on glomerular filtration and damage • Empagliflozin and finerenone have been
Slide 3: The CONFIDENCE Trial
The CONFIDENCE Trial CONFIDENCE was designed to evaluate whether empagliflozin (SGLT2i) plus finerenone (nsMRA) would reduce UACR more than either therapy alone Empagliflozin (10 mg daily) plus finerenone placebo N=800 Primary endpoint R Finerenone (10 or 20 mg daily) plus empagliflozin placebo Rela
Slide 4: Baseline Characteristics in CONFIDENCE, by BMI
Baseline Characteristics in CONFIDENCE, by BMI Higher baseline BMI in CONFIDENCE associated with: Self-reported Black or White race Systolic blood pressure, UACR, HbA1c, and history of ASCVD Serum potassium and self- reported Asian race Background treatment with diuretics, insulin, and GLP-1RA
Slide 5: Benefits of Empagliflozin + Finerenone on UACR Consistent Across the BMI Spectrum
Benefits of Empagliflozin + Finerenone on UACR, vs. Monotherapy, were Consistent Across the BMI Spectrum Mean change in UACR at day 180, according to baseline BMI within each treatment arm, estimated through linear regression adjusted for baseline UACR, age, sex, race, and protocol-specified stratif
Slide 6: Treatment Effects on CKM Risk Factors, by BMI
Treatment Effects on CKM Risk Factors, by BMI Mean change in each CKM parameter at day 180, according to baseline BMI within each treatment arm, estimated through linear regression adjusted for baseline parameter values, age, sex, race, and protocol-specified stratification factors.
Slide 7: Body Weight Effects & UACR Change vs. Body Weight
Body Weight Effects & UACR Change vs. Body Weight Absolute Body Weight Change >5% Body Weight Change ≥30% UACR Reduction by ∆BW
Slide 8: Key Findings and Conclusions
Key Findings and Conclusions • Benefits of empagliflozin + finerenone on UACR reduction, versus each therapy individually, were consistent irrespective of BMI • Modest reductions in body weight were observed with all treatments, and may be an important ancillary benefit in this population • Greater